hotspot -WSS

hotspot

author：hotspot 2025-10-04 11:47:42 - browse：52

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Bristol Myers buys into radiopharmaceuticals with RayzeBio

WSS

CDC director unscathed in first congressional testimony

Medicare Advantage beneficiaries sue Humana over algorithm use

J&J to emphasize cancer drugs, stop much of its vaccine research

How to pay for weight loss drugs and save Medicare

SEC charges former device maker CEO with $41 million fraud

What don’t we know about an Alzheimer’s drug side effect?

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

entertainment

Alkermes shareholders re

SEC charges former device maker CEO with $41 million fraud

Novavax promises a turnaround & Lilly roils the obesity market

What don’t we know about an Alzheimer’s drug side effect?

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

J&J to emphasize cancer drugs, stop much of its vaccine research

Heart attack and stroke risk calculators need revising

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Will the market for weight loss drugs really reach $100 billion?

leisure time

How to pay for weight loss drugs and save Medicare

U.K. Biobank has 500,000 peoples' genome sequences available

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Christmas in the PICU brings some surprising joy

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Fetal surgery at risk from Dobbs and new abortion restrictions

knowledge

hotspot

hotspot

hotspot